In this study, we established a simple screening method to identify a deletion of exon 19 and a point mutation of exon 21 of the EGFR gene, and we detected these mutations in 136 cases (42.2%) with adenocarcinoma and two cases with other cell types. The gene discussed is EGFR; the disease is adenocarcinoma.